1-6 of 6
Tamar Uziel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

Chewei Anderson Chang, Ethan Emberley, Aloma L. D'Souza, Weilong Zhao, Cormac Cosgrove, Karen Parrish, Diya Mitra, Elmer Payson, Anatol Oleksijew, Paul Ellis, Luis Rodriguez, Ryan Duggan, Cara Hrusch, Loren Lasko, Wissam Assaily, Pingping Zheng, Wei Liu, Axel Hernandez, Jr., Kimberley McCarthy, Zhaomei Zhang, Geunbae Rha, Zhensheng Cao, Yingchun Li, Olivia Perng, Jos Campbell, Gloria Zhang, Tyler Curran, Milan Bruncko, Christopher C. Marvin, Adrian Hobson, Michael McPherson, Tamar Uziel, Marybeth A. Pysz, Xi Zhao, Alex Bankovich, Joel Hayflick, Michael McDevitt, Kevin J. Freise, Susan Morgan-Lappe, James W. Purcell
Journal: Blood
Blood (2024) 144 (7): 757–770.
https://doi.org/10.1182/blood.2024023849
Published: 2024
Includes: Supplemental data
Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Clinical Trials & Observations
Stephen K. Tahir, Emiliano Calvo, Benedito A. Carneiro, Junichiro Yuda, Aditya Shreenivas, Mojca Jongen-Lavrencic, Eelke Gort, Kenichi Ishizawa, Daniel Morillo, Carla Biesdorf, Morey Smith, Dong Cheng, Monica Motwani, David Sharon, Tamar Uziel, Dimple A. Modi, Fritz G. Buchanan, Susan Morgan-Lappe, Bruno C. Medeiros, Darren C. Phillips
Journal: Blood
Blood (2023) 141 (17): 2114–2126.
https://doi.org/10.1182/blood.2022017333
Published: 2023
Includes: Supplemental data
Journal Articles

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

Deeksha Vishwamitra, Christine Mantis, PhD, Dipica Haribhai, PhD, Tamar Uziel, PhD, Joel D. Leverson, PhD, James M. Pauff, MD PhD, Orlando F. Bueno, MD PhD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1896.
https://doi.org/10.1182/blood-2019-128672
Published: 2019
Journal Articles

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Xiaoyu Lin, Tamar Uziel, PhD, Xin Lu, Lu Zhang, Xiaoli Huang, Qi Zhang, PhD, Antonio Cavazos, Lina Han, PhD, Yu Shen, Marina Y Konopleva, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1369.
https://doi.org/10.1182/blood-2019-128618
Published: 2019
Journal Articles

The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity

Rebecca Mathew, PhD, Dipica Haribhai, PhD, Fred Kohlhapp, PhD, Ryan Duggan, Paul Ellis, Jacob J Riehm, Valerie A Robinson, Yan Y Shi, Anahita Bhathena, PhD, Joel D. Leverson, PhD, William N Pappano, Cherrie K Donawho, PhD, Tamar Uziel, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2018-99-113134
Published: 2018
Journal Articles

Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, Tamar Uziel, PhD, Qi Zhang, PhD, Lina Han, PhD, Antonio Cavazos, MSc, Yu Shen, Marina Y. Konopleva, MD PhD, Xiaoyu Lin, Xin Lu, Lu Zhang
Journal: Blood
Blood (2018) 132 (Supplement 1): 1439.
https://doi.org/10.1182/blood-2018-99-116912
Published: 2018